We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

By LabMedica International staff writers
Posted on 02 Jul 2025

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. More...

Often referred to as the "king" of all cancers, it is notorious for spreading rapidly to other parts of the body if not detected early. However, early detection is extremely difficult due to the absence of distinct molecular markers and clinical symptoms. As a result, the disease is typically diagnosed at an advanced stage, by which time surgical interventions are largely ineffective. For this reason, early detection and accurate stratification of pancreatic cancer stages are crucial for improving patient outcomes. Now, a new study reveals that oncologists adopting artificial intelligence (AI) in their tests to detect pancreatic cancer at an early stage can also understand how the deadly disease will develop. While AI-enabled prognosis still remains in its initial stage, the researchers believe it has the potential to pave the way for the provision of individualized healthcare and treatment of pancreatic cancer patients.

Scientists at the University of Sharjah (Sharjah, UAE) arrived at the groundbreaking conclusion after an extensive review of pancreatic cancer-related scientific literature, offering what they describe as a concise overview of how AI is being applied to the diagnosis, prognosis, and treatment of the disease. Their work explores several components of AI integration, particularly its role in enhancing image analysis and transforming computer-aided diagnostic systems. They highlight the relevance of multiomics—an approach that integrates various types of biological data—and stress the importance of collaboration among clinicians, data analysts, and scientists. By leveraging AI’s processing power, the technology can assist in identifying tumors at early stages, assessing patient risk, and forming long-term treatment strategies. Although these systems are not always easy to understand or operate, researchers are actively developing explainable AI techniques—such as feature relevance scores, infographics, and natural language explanations—to make AI tools more accessible and interpretable in clinical settings.

The study details how these AI tools, though complex, are being refined for practical application in oncology. The authors report that AI can support personalized treatment planning by analyzing patient-specific data to predict responses to therapies like immunotherapy, chemotherapy, radiation, and surgery. They also highlight the growing interest in integrating Internet of Things (IoT) technologies into pancreatic cancer care. Published in the Beni-Suef University Journal of Basic and Applied Sciences, the research supports the high utility of machine learning models in early detection, which can significantly reduce pancreatic cancer morbidity and mortality. Although clinical use remains somewhat sophisticated, the emergence of explainable AI is expected to ease this burden and facilitate wider adoption. The researchers call for continued development of AI-based pancreatic cancer solutions to ultimately build semi-autonomous or fully autonomous systems that can reduce clinician burden, increase productivity, and improve outcomes.

“AI ought to help oncologists create personalized treatment regimens by combining patient-specific data. It is being utilized to predict how patients react to therapies like immunotherapy, chemotherapy, radiation therapy, and surgery,” stated the authors.


New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Serological Pipet Controller
PIPETBOY GENIUS
New
Automated Biochemical Analyzer
iBC 900
New
DNA/RNA Extraction/Purification Kit
Nucleic Acid Extraction or Purification Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.